A Case of Slipping Quality biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Strides Pharma teams up with Ennaid Therapeutics to manufacture COVID-19 drug
Strides Pharma teams up with Ennaid Therapeutics to manufacture COVID-19 drug
15 June 2021 | News Ennaid Therapeutics will produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19
Image Credit: shutterstock.com
Bengaluru-based Strides Pharma Science has announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with US-based Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.
Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms.
Hyderabad-headquartered Gland Pharma on Tuesday said it had inked a pact with Russian Direct Investment Fund (RDIF) to supply 252 million doses of the Covid-19 vaccine Sputnik V. This is part of the Russian sovereign wealth fund’s efforts to increase manufacturing capacities in India to make for the country and to augment global supplies. Sources said Bengaluru-based Strides Pharma Science, too, is in fray for contract manufacturing the Sputnik V. Another Hyderabad-based player, Hetero, will supply 100 million doses of the vaccine. RDIF has lined up 250 million doses for India over the next 12 months, and the rest will be for global supplies.
Cipla recalls 5.8 lakh packets of gastric ulcer treatment drug from US market
The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary
PTI | January 10, 2021 | Updated 14:07 IST
The USFDA cited cross-contamination with other products as the reason for the company recalling the product
Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said.